

## SEQUENCE LISTING

<110> Applied Research Systems ARS holding  
 5 <120> THERAPEUTIC USES OF CHEMOKINE VARIANTS  
 <130> WO933  
 <160> 5  
 10 <170> PatentIn version 3.0  
  
 <210> 1  
 15 <211> 76  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <223> Human CCL2  
 20 <400> 1  
  
 Gln Pro Asp Ala Ile Asn Ala Pro Val Thr Cys Cys Tyr Asn Phe Thr  
 1 5 10 15  
 25 Asn Arg Lys Ile Ser Val Gln Arg Leu Ala Ser Tyr Arg Arg Ile Thr  
 20 25 30  
 Ser Ser Lys Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Ile Val Ala  
 30 35 40 45  
 Lys Glu Ile Cys Ala Asp Pro Lys Gln Lys Trp Val Gln Asp Ser Met  
 50 55 60  
 35 Asp His Leu Asp Lys Gln Thr Gln Thr Pro Lys Thr  
 65 70 75  
  
 <210> 2  
 40 <211> 76  
 <212> PRT  
 <213> synthetic construct  
 <220>  
 <223> Human CCL2-P8A  
 45 <400> 2  
  
 Gln Pro Asp Ala Ile Asn Ala Ala Val Thr Cys Cys Tyr Asn Phe Thr  
 1 5 10 15  
 50 Asn Arg Lys Ile Ser Val Gln Arg Leu Ala Ser Tyr Arg Arg Ile Thr  
 20 25 30  
 Ser Ser Lys Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Ile Val Ala  
 55 35 40 45  
 Lys Glu Ile Cys Ala Asp Pro Lys Gln Lys Trp Val Gln Asp Ser Met  
 50 55 60

Asp His Leu Asp Lys Gln Thr Gln Thr Pro Lys Thr  
 65 70 75

5  
 <210> 3  
 <211> 76  
 <212> PRT  
 <213> synthetic construct  
 10 <220>  
 <223> Human CCL2\*  
 <400> 3

15 Gln Pro Asp Ala Ile Asn Ala Pro Val Thr Cys Cys Tyr Asn Phe Thr  
 1 5 10 15  
 Asn Arg Lys Ile Ser Val Gln Arg Leu Ala Ser Tyr Arg Arg Ile Thr  
 20 20 25 30  
 Ser Ser Lys Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Ile Val Ala  
 35 40 45  
 Lys Glu Ile Cys Ala Asp Pro Lys Gln Lys Trp Val Gln Asp Ser Ile  
 25 50 55 60  
 Asp His Leu Asp Lys Gln Thr Gln Thr Pro Lys Thr  
 65 70 75

30  
 <210> 4  
 <211> 76  
 <212> PRT  
 <213> synthetic construct  
 35 <220>  
 <223> Human CCL2\*-P8A  
 <400> 4

40 Gln Pro Asp Ala Ile Asn Ala Ala Val Thr Cys Cys Tyr Asn Phe Thr  
 1 5 10 15  
 Asn Arg Lys Ile Ser Val Gln Arg Leu Ala Ser Tyr Arg Arg Ile Thr  
 45 20 25 30  
 Ser Ser Lys Cys Pro Lys Glu Ala Val Ile Phe Lys Thr Ile Val Ala  
 35 40 45  
 Lys Glu Ile Cys Ala Asp Pro Lys Gln Lys Trp Val Gln Asp Ser Ile  
 50 50 55 60  
 Asp His Leu Asp Lys Gln Thr Gln Thr Pro Lys Thr  
 65 70 75

55  
 <210> 5  
 <211> 331,  
 <212> PRT

&lt;213&gt; synthetic construct

&lt;220&gt;

&lt;223&gt; Human CCL2-P8A\_IgG1 fusion protein

5 &lt;400&gt; 5

Met Lys Val Ser Ala Ala Leu Leu Cys Leu Leu Leu Ile Ala Ala Thr  
 1 5 10 15  
 Phe Ile Pro Gln Gly Leu Ala Gln Pro Asp Ala Ile Asn Ala Ala Val  
 20 25 30  
 Thr Cys Cys Tyr Asn Phe Thr Asn Arg Lys Ile Ser Val Gln Arg Leu  
 35 40 45  
 Ala Ser Tyr Arg Arg Ile Thr Ser Ser Lys Cys Pro Lys Glu Ala Val  
 50 55 60  
 Ile Phe Lys Thr Ile Val Ala Lys Glu Ile Cys Ala Asp Pro Lys Gln  
 65 70 75 80  
 Lys Trp Val Gln Asp Ser Met Asp His Leu Asp Lys Gln Thr Gln Thr  
 85 90 95  
 Pro Lys Thr Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro  
 100 105 110  
 Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro  
 115 120 125  
 Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr  
 130 135 140  
 Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn  
 145 150 155 160  
 Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg  
 165 170 175  
 Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val  
 180 185 190  
 Leu His Asn Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser  
 195 200 205  
 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys  
 210 215 220  
 Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu  
 225 230 235 240  
 Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe  
 245 250 255  
 Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Gln Gly Gln Pro Glu  
 260 265 270  
 Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe

275 280 285

Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly  
290 295 300

5

Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr  
305 310 315 320

10 Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
325 330